Status:
COMPLETED
Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Collaborating Sponsors:
University of Copenhagen
Conditions:
Hyperglycemia
Hyperglucagonemia
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The incretin hormone glucagon-like peptide-1 (GLP-1) has known insulinotrophic and glucagonostatic properties. However, inpatients with type 2 diabetes mellitus (T2DM)it is shown, that the beta cell s...
Eligibility Criteria
Inclusion
- T2DM according to WHO criteria
- Written consent
- Age \> 18 years
Exclusion
- Kidney or hepatic disease
- Treatment with insulin or glitazone
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00862589
Start Date
October 1 2006
End Date
March 1 2007
Last Update
March 18 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.